INCR

InterCure Ltd. (INCR) | Rumor.io

InterCure

INCR

Attention (50-day avg)0%

Attention rank (50-day avg)#2,498

Bullish sentiment (50-day avg)100%

Price to earnings ratio22.2

Market capitalization76.4M

Earnings per share-1.08

Dividend yield (TTM)—

Revenue (annual)270.2M

Net income (annual)-36.8M

Social

What share of all stock conversation is about INCR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Aug 24

$INCR gapped up, but the volume isn't there yet, and more volume is needed for confirmation.
InterCure finalized a NIS 230 million (~US$77 million) settlement for war-related indirect damages, which was partly already received as advance payments.
$INCR stock jumped ~21.6% to $5.18 after the settlement, strengthening its balance sheet and funding recovery efforts.

Generated by AI

Sentiment

Of the messages about INCR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +45.45
Bearish	—	—	—	0% -45.45

Bullish· Sep 3

$INCR has seen a 4 times YOY revenue growth, according to its record-breaking second quarter financial results.
The company has successfully uplisted to NASDAQ, a major milestone for InterCure Ltd.
$INCR has the potential to reach new highs, with some investors expecting it to hit $8 or $10 in a short amount of time.

Bearish· Nov 9

$INCR missed EPS and revenue estimates, with a 8c miss on EPS and a $15.69M miss on revenue.
$INCR was part of a group of 71 stocks that dropped in value.
$INCR's Q4 EPS guidance fell below consensus estimates.

Generated by AI

Topics

Of the messages about INCR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	0%	5.98%
Announcements	—	—	50%	84.78%
Controversies	—	—	50%	2.17%
Analysts	—	—	0%	0%
Earnings	—	—	0%	7.07%
Macro	—	—	0%	0%

Earnings· Nov 9

$INCR reported FQ3 earnings of 54c EPS and $592.21M Revs, missing Estimize EPS consensus by 8c and revenue consensus by $15.69M.
INC Research Holdings announces earnings of $0.54 EPS, missing estimates, with $592.21M revenue.
$INCR guides Q4 EPS below consensus after missing estimates in FQ3.

Announcements· May 16

InterCure Ltd. (INCR) reported record-breaking Q1 financial results, with revenue increasing 3% sequentially to C$34 million.
The company's Q1 revenue growth of 9% sequentially from the prior quarter marked a strong start to 2022.
InterCure announced its Q1 2022 results and plans to hold a conference call, with details available on the SEC Form SC 13G filing.

Generated by AI

Community

Of the messages about INCR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	69.53%
Newcomers	0%	0%	0%	30.47%

Regulars· Apr 3

InterCure Ltd. ($INCR) has seen a significant increase in put volume, with 47 puts being traded, representing 686% of the 30-day average put volume of 6.85.
The company has rescheduled its 2022 full year results conference call, with the new date not specified in the available information.
InterCure Ltd. ($INCR) has announced its record fourth quarter and fiscal year end 2022 results, with details available in its 6-K filing.

Newcomers· Aug 24

The settlement between InterCure and the Israeli government for war-related damages has been finalized, with InterCure receiving approximately $77 million.
The news has caused InterCure's stock to jump 21.6% to $5.18, with some users predicting further growth to $40-50.
The settlement has strengthened InterCure's balance sheet and funded its recovery efforts, with some users expecting the company to be a good investment opportunity.

Generated by AI

News

InterCure Regains Nasdaq Compliance After Delisting Warning

Detailed price information for Intercure Ltd (INCR-Q) from The Globe and Mail including charting and trades.

21d agoThe Globe and Mail

InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement

NEW YORK and HERZLIYA, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (“InterCure” or the “Company”) anno...

21d agomarkets.businessinsider.com

InterCure Regains Nasdaq Compliance

InterCure (INCR) said Tuesday it has regained compliance with Nasdaq's minimum bid price listing rul

22d agoYahoo Finance

InterCure Raises $5 Million in August Private Placement to Rebuild Nir Oz Facility

Detailed price information for Intercure Ltd (INCR-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

InterCure (INCR) Finalized a $77M Settlement, but How Much New Cash Will it Receive?

InterCure Ltd. (NASDAQ:INCR) finalized a NIS 230 million, or approximately $77 million, settlement with Israeli authorities covering indirect damages from the October 7, 2023 attacks and subsequent war. The more relevant figure for investors is approximately $43 million. The $77 million represents aggregate compensation rather than a new cash payment. InterCure Ltd. (NASDAQ:INCR) previously received […]

1mo agoYahoo Finance

InterCure Secures NIS 230 Million War-Damage Settlement to Rebuild Nir Oz Facility

Detailed price information for Intercure Ltd (INCR-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about INCR also mention

#	Name	Attention
1	IM Cannabis Corp.IMCC	0%+0
2	Amplify Seymour Cannabis ETFCNBS	0.02%+0.01
3	AdvisorShares Pure US Cannabis ETFMSOS	0.49%-0.18
4	Village Farms International Inc.VFF	0.01%-0.01
5	Organigram Global Inc.OGI	0%0
6	AdvisorShares MSOS Daily Leveraged ETFMSOX	0.15%-0.05
7	Innovative Industrial Properties, Inc.IIPR	0.42%+0.42
8	Agrify Corp.AGFY	0%0
9	Greenlane Holdings, Inc. Class A Common StockGNLN	0%0
10	Flora Growth Corp.FLGC	0%new

InterCure Ltd.

Healthcare
Drug Manufacturers - Specialty & Generic

InterCure Ltd. is an Israel-based pharmaceutical cannabis company focused on the production, manufacturing, and distribution of medical cannabis products. Through its subsidiaries, it develops and supplies pharmaceutical-grade dried cannabis inflorescences and cannabis extracts for medical use in Israel and international markets. The company also operates in the broader biomed sector, reflecting a business mix that combines cannabis operations with investments in healthcare-related portfolio companies. InterCure serves patients, healthcare providers, and distribution partners through a vertically integrated model that spans research, cultivation, production, and delivery of cannabis-based therapies. Headquartered in Herzliya, Israel, InterCure plays a significant role in the regulated medical cannabis market by emphasizing clinical-grade standards and licensed production capabilities.

Website

Location

85 Medinat ha-Yehudim Street

Herzliya, 4676670

Israel

Social

What share of all stock conversation is about INCR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% +0

Aug 24

$INCR gapped up, but the volume isn't there yet, and more volume is needed for confirmation.
InterCure finalized a NIS 230 million (~US$77 million) settlement for war-related indirect damages, which was partly already received as advance payments.
$INCR stock jumped ~21.6% to $5.18 after the settlement, strengthening its balance sheet and funding recovery efforts.

Generated by AI

Sentiment

Of the messages about INCR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +45.45
Bearish	—	—	—	0% -45.45

Bullish· Sep 3

$INCR has seen a 4 times YOY revenue growth, according to its record-breaking second quarter financial results.
The company has successfully uplisted to NASDAQ, a major milestone for InterCure Ltd.
$INCR has the potential to reach new highs, with some investors expecting it to hit $8 or $10 in a short amount of time.

Bearish· Nov 9

$INCR missed EPS and revenue estimates, with a 8c miss on EPS and a $15.69M miss on revenue.
$INCR was part of a group of 71 stocks that dropped in value.
$INCR's Q4 EPS guidance fell below consensus estimates.

Generated by AI

Topics

Of the messages about INCR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	0%	5.98%
Announcements	—	—	50%	84.78%
Controversies	—	—	50%	2.17%
Analysts	—	—	0%	0%
Earnings	—	—	0%	7.07%
Macro	—	—	0%	0%

Earnings· Nov 9

$INCR reported FQ3 earnings of 54c EPS and $592.21M Revs, missing Estimize EPS consensus by 8c and revenue consensus by $15.69M.
INC Research Holdings announces earnings of $0.54 EPS, missing estimates, with $592.21M revenue.
$INCR guides Q4 EPS below consensus after missing estimates in FQ3.

Announcements· May 16

InterCure Ltd. (INCR) reported record-breaking Q1 financial results, with revenue increasing 3% sequentially to C$34 million.
The company's Q1 revenue growth of 9% sequentially from the prior quarter marked a strong start to 2022.
InterCure announced its Q1 2022 results and plans to hold a conference call, with details available on the SEC Form SC 13G filing.

Generated by AI

Community

Of the messages about INCR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	69.53%
Newcomers	0%	0%	0%	30.47%

Regulars· Apr 3

InterCure Ltd. ($INCR) has seen a significant increase in put volume, with 47 puts being traded, representing 686% of the 30-day average put volume of 6.85.
The company has rescheduled its 2022 full year results conference call, with the new date not specified in the available information.
InterCure Ltd. ($INCR) has announced its record fourth quarter and fiscal year end 2022 results, with details available in its 6-K filing.

Newcomers· Aug 24

The settlement between InterCure and the Israeli government for war-related damages has been finalized, with InterCure receiving approximately $77 million.
The news has caused InterCure's stock to jump 21.6% to $5.18, with some users predicting further growth to $40-50.
The settlement has strengthened InterCure's balance sheet and funded its recovery efforts, with some users expecting the company to be a good investment opportunity.

Generated by AI

InterCure

Social

Aug 24

Bullish· Sep 3

Bearish· Nov 9

Earnings· Nov 9

Announcements· May 16

Regulars· Apr 3

Newcomers· Aug 24

InterCure Regains Nasdaq Compliance After Delisting Warning

InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement

InterCure Regains Nasdaq Compliance

InterCure Raises $5 Million in August Private Placement to Rebuild Nir Oz Facility

InterCure (INCR) Finalized a $77M Settlement, but How Much New Cash Will it Receive?

InterCure Secures NIS 230 Million War-Damage Settlement to Rebuild Nir Oz Facility

Also Discussed

InterCure Ltd.

Company Information

Location

InterCure Regains Nasdaq Compliance After Delisting Warning

InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement

InterCure Regains Nasdaq Compliance

InterCure Raises $5 Million in August Private Placement to Rebuild Nir Oz Facility

InterCure (INCR) Finalized a $77M Settlement, but How Much New Cash Will it Receive?

InterCure Secures NIS 230 Million War-Damage Settlement to Rebuild Nir Oz Facility

Also Discussed

Social

Aug 24

Bullish· Sep 3

Bearish· Nov 9

Earnings· Nov 9

Announcements· May 16

Regulars· Apr 3

Newcomers· Aug 24